Showing posts with label dexpramipexole in hypereosinophilic syndromes meets its co-primary endpoints. Show all posts
Showing posts with label dexpramipexole in hypereosinophilic syndromes meets its co-primary endpoints. Show all posts
Thursday, June 7, 2018

Phase 2 study of dexpramipexole in hypereosinophilic syndromes meets its co-primary endpoints

›
Knopp Biosciences LLC today announced the publication of a report in the journal  Blood that a Phase 2 study of dexpramipexole in hypereos...